EGFR mutations, also common in NSCLC, may promote immune escape through the upregulation of PD-(L)1 and CTLA-4, and EGFR amplifications have been implicated in hyperprogression following ICI therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.